- Raised $60M funding round, Jun 2021
- Raised $25M funding round, Dec 2019
- Raised $5M funding round, Jun 2012
About
Notal Vision has developed a cloud-based platform designed to effectively and efficiently address large unmet diagnostic, economic, and social needs in the area of ophthalmology. The company's integrated platform uses AI algorithms to detect and provide diagnostic decision support, driving at-home testing and patient-activated treatment. Using a monthly recurring subscription service model, the platform provides the basis for cost-effective solutions that can enhance both compliance and outcomes.
Notal's ForeseeHome is an FDA-approved home monitoring test that supports earlier detection of wet age-related macular degeneration (AMD) in people with intermediate dry AMD. It is available only by physician order and covered by US Medicare.
Notal also develops a home optical coherence tomography (OCT) solutions, noninvasive imaging technology for viewing retinal anatomy and assessing the need for treatment of age-related eye diseases that lead to blindness. In December 2018, Notal's Home OCT was granted Breakthrough status by the FDA and selected to participate in the FDA's OCT Innovation Pilot program.
Notal's OCT Analyzer is a computational image analysis algorithm designed to provide automated detection of fluid in exudative retinal diseases.
Funding history · 6 rounds · $94.0M total
Q&A
- What is Notal Vision's primary focus?
- Notal Vision specializes in remote patient monitoring for retinal diseases, utilizing a cloud-based platform with AI algorithms for diagnostic decision support and at-home testing.
- What is Notal Vision's FDA-approved product?
- Notal Vision's ForeseeHome is an FDA-approved home monitoring test designed for the earlier detection of wet age-related macular degeneration (AMD) in individuals with intermediate dry AMD. It is available by physician order and covered by US Medicare.
- What is the status of Notal Vision's Home OCT solution?
- In December 2018, Notal Vision's Home Optical Coherence Tomography (OCT) solution was granted Breakthrough status by the FDA and selected to participate in the FDA's OCT Innovation Pilot program. This technology provides noninvasive imaging for viewing retinal anatomy.
- What is Notal Vision's OCT Analyzer?
- The OCT Analyzer is a computational image analysis algorithm developed by Notal Vision to provide automated detection of fluid in exudative retinal diseases.
- When was Notal Vision founded?
- Notal Vision was founded in August 2000.
- How many employees does Notal Vision have?
- Notal Vision has 51-200 employees.
- What was Notal Vision's most recent funding round?
- Notal Vision raised $60,000,000 in June 2021. Investors in this round included Elron Ventures and Evergreen Venture Partners.
- What is Notal Vision's total funding raised to date?
- Notal Vision has raised a total of $94,050,000 to date.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | notalvision.com |
|---|---|
| linkedin.com/company/52831 | |
| YouTube | youtube.com/channel/UCE_LNr1jOStRfPY_DH7ATZg |
| Wikidata | wikidata.org/wiki/Q107519312 |
Identifiers & details
| Founded | 2000-8 |
|---|---|
| Employees (exact) | 86 |
| Offices | Manassas |
| Wikidata QID | Q107519312 |
Radar intelligence
Patents
| EPO | 11 |
|---|
Web history (Wayback)
| Domain | notalvision.com |
|---|
Wikidata
| QID | Q107519312 |
|---|
Certificate / subdomain footprint
| Subdomains | 24 |
|---|